We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

News   Mar 23, 2018 | Original story from The Wyss Institute

 
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

Made of the polymer that’s used in biodegradable sutures, this aspirin-sized device is designed to deliver immunotherapy agents that activate the immune system against tumors. Image courtesy of the Wyss Institute at Harvard University

 
 
 

RELATED ARTICLES

Brain Cancer Potentially Resists Immunotherapies by Trapping T Cells in Bone Marrow

News

Certain brain cancers are associated with low numbers of immune system T-cells circulating in the peripheral blood. Low T-cell numbers can be a side-effect of cancer treatment. But it now appears that there is more to the story of these missing T-cells.

READ MORE

Retinoic Acid may Improve Immune Response Against Melanoma

News

Scientists have found a promising strategy to remove one of melanoma’s most powerful defenses, leading to more immune system activity directed at melanoma.

READ MORE

PCR Assay Helps ID Sarcoma Mutations

News

Sarcomas are rare tumors that are often misdiagnosed. A report in the Journal of Molecular Diagnostics describes a new assay, anchored multiplex PCR (AMP)-based targeted next-generation-sequencing (NGS), that is better able to identify genetic diagnostic markers of the cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE